News & Editorial

GLP-1 advancements, regulatory developments, and compound comparisons.

News · May 28, 2026

What Happened to Peptide Sciences?

"Peptide Sciences" is one of the most-searched names in the research-peptide world. Here's what people are actually asking, why the search interest persists, and how to evaluate any vendor — without us pretending to be a company we're not.

News · May 20, 2026

The GLP-1 Pipeline in 2026: Beyond Semaglutide and Tirzepatide

Dual and triple incretin agonists, oral formulations, and muscle-preservation combinations are reshaping the metabolic landscape. A neutral look at what's approved, what's in trials, and what's still hype.